Anzeige
Mehr »
Login
Montag, 06.05.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
+56,25% in 5 Tagen: Genialer Schachzug - diese Übernahme verändert alles
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
40 Leser
Artikel bewerten:
(0)

Mr Claude Poulin nominated as President and CEO of Neuro-Biotech Corp.

BASEL, Switzerland, Sept. 17 /PRNewswire-FirstCall/ -- Neuro-Biotech Corp. (PINKSHEETS: MRES) (OTCQB: MRES) announces the nomination of Doctor Claude Poulin as President and CEO.

Mr Barry Somervail comments on today's announcement "Following the change of the Company's direction during the summer of 2010, I stayed on as a member of board of directors in order to facilitate the transition process, and now that this process is complete I am pleased to announce the relinquishment of my position and duties to Dr. Poulin.

Dr. Claude Poulin, 71, a general practitioner with over 40 years of experience, owns and operates a Lachute medical clinic where he continues to practice to this day. Dr. Poulin will bring his medical experience and expertise, as well as his knowledge of patients to the board. He is also looking forward to highlighting the value of the various applications of Neuro-Biotech products within the medical community.

The appointment of Dr. Claude Poulin became effective upon the filing of the 8k Form with the relevant authorities.

Forward Looking Statements

This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

Neuro-Biotech Corp.

CONTACT: Dr. Claude Poulin, Neuro-Biotech Corp., 41-61-500-0516,
info@neuro-agora.com

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2010 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.